(Length of discussion - 9 minutes)

Dr. Jelle Barentsz provides his perspective on treating a patient with a rising PSA and is seeking diagnosis options.  During this discussion held at the Radiological Society of North America (RSNA) 2017 conference, he shares that he would not recommend a 12-core systematic biopsy because it is not targeted.  40% of patients with a trans-rectal ultrasound guided (TRUS) biopsies will reveal insignificant cancer, which will result in over-diagnosis. Dr. Barentsz recommends multiparametric MRI, which is quick, easy, and can significantly reduce over-diagnoses from 40% to 80%.  He also discusses the need for a radiologist who specialize in reading prostate MRIs, which can be difficult to do, as well as establishing specific rules and guidelines to make prostate cancer diagnoses through multiparametric MRI more consistent globally. 


Biography: 

Jelle Barentsz, MD, Phd is a Professor of Radiology and Chair Prostate MR - Reference Center, Radboud University Medical Center,  Nijmegan, Netherlands. Dr. Barentsz is one of the world’s leading authorities on prostate mp MRI imaging.

Co-interviewers:
John Fortin is a retired Fellow in the Society of Actuaries and a patient advocate
Henry Oat is a Patient Coordinator at Desert Medical Imaging and a patient advocate